10x Genomics, Inc. (TXG)
TXGNASDAQ-GSBiotechnology: Laboratory Analytical Instruments
$65.84
+7.35 (+12.57%) today
Closed, Nov 9, 4:00 PM ET
- Market cap
- $8.48bn
- P/E
- –
- EPS, last 4 quarters
- $-0.5200
- Dividend yield
- –
- Day range
- –
- 52-week range
- $13.58 to $102.81
- Average volume
- 3.44m
- Previous close
- $58.49
Analysts
15 coveringHold6 buy, 9 hold, 0 sell
Targets a year out average $74.15, +12.6% from here
Earnings
next estimate $-0.1800Next report
Dec 2025
+31.6%
Mar 2026
+65.5%
Jun 2026
+39.1%
Sep 2026
+48.3%
estimate reported, and the surprise
Financials
| Quarter | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|
| Revenue | $166.03m | $150.84m | $151.04m | $150.67m |
| Gross profit | $113.05m | $106.18m | $112.50m | $112.93m |
| Operating income | -$19.54m | -$17.05m | -$19.55m | -$16.06m |
| Net income | -$16.25m | -$13.47m | -$17.93m | -$19.43m |
Last four quarters: revenue $618.58m, margin -10.8%, free cash flow $93.77m
News
8 latest- 10x Genomics Launches Sentira AI Tool to Simplify Cell AnalysisZacks · 3 days ago
- TXG Q3 Earnings Call Highlights Atera Launch and Raised OutlookZacks · 4 days ago
- What 10x Genomics (TXG) Said on Its Q3 Earnings CallMarketBeat · 4 days ago
- 10x Genomics, Inc. Reports Third Quarter 2026 Financial Results and Raises Full Year Revenue GuidanceFintel · 4 days ago
- Meet the Unstoppable Vanguard ETF Beating the S&P 500 and the Dow Jones in 2026The Motley Fool · 4 days ago
- 10x Genomics (TXG) Q3 2026 Earnings Call TranscriptThe Motley Fool · 4 days ago
- Compared to Estimates, 10x Genomics (TXG) Q3 Earnings: A Look at Key MetricsZacks · 4 days ago
- 10x Genomics (TXG) Reports Q3 Loss, Beats Revenue EstimatesZacks · 4 days ago
The company
10x Genomics is a life science technology company building products to accelerate the mastery of biology and advance human health. Our integrated research solutions include instruments, consumables and software for single cell and spatial biology, which help academic and translational researchers and biopharmaceutical companies understand biological systems at a resolution and scale that matches the complexity of biology. Our products are behind breakthroughs in oncology, immunology, neuroscience and more, fueling powerful discoveries that are transforming the world's understanding of health and disease.
- Sector
- Industrials
- Industry
- Biotechnology: Laboratory Analytical Instruments
- Exchange
- NASDAQ-GS
- Region
- North America
- Website
- 10xgenomics.com
Often looked at with it
Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.